**Supplementary material**

Table S1:Demographic characteristics and medications in study subjects

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables**  | **G1 controls** | **G1 T2DM** | **p-value#** | **G2 controls** | **G2 T2DM**  | **p-value** |
| Gender i) Maleii) Female | 23 (57.5%)17 (42.5%) | 26 (65%)14 (35%) | 0.491 | 16 (40%)24 (60%) | 26 (65%)14 (35%) | 0.025 |
| Family historyi) Diabetesii) Diabetes and HTNiii) HTNiv) None  | 6 (15%)3 (7.5%)031 (77.5%) | 26 (65%)2 (5%)1 (2.5%)11 (27.5%) | <0.001 | 7 (17.5%)2 (5%)031 (77.5%) | 28 (70%)4 (10%)08 (20%) | <0.001 |
| OHA medications i) Metforminii) Non-metforminiii) Combinationsaiv) Not taken | ---- | 10 (25%)5 (12.5%)22 (55%)3 (7.5%) | - | ---- | 8 (20%)4 (10%)27 (67.5%)1 (2.5%) | - |
| Statin/Aspirin i) Statinii) Aspiriniii) Bothbiv) Not taken | ---- | 6 (15%)3 (7.5%)10 (25%)21 (52.5%) | - | ---- | 4 (10%)8 (20%)12 (30%)16 (40%) | - |

p-value using Chi-square test or Fischer exact test; Categorical variables represented in count (% frequency); HTN: hypertension; OHA: oral hypoglycemic agent; aboth metformin and other classes of OHA; bstatin and aspirin;

Table S2: Oxidative stress, pro-inflammatory cytokines, and senescence markers in T2DM patients according to the duration of diabetes (years)

|  |  |  |
| --- | --- | --- |
| **Variables** | **Duration of diabetes** | **p-value** |
| **< 2 years (n=27)** | **2-5 years****(n=22)** | **> 5 years****(n=31)** |
| MDA (µmol/L) | 8.64(6.97-10.97) | 8.1(5.65-9.77) | 7.9(5.72-9.96) | 0.373 |
| oxLDL (µg/mL) | 1.1(0.71-1.85) | 0.89(0.69-1.7) | 1.03(0.52-1.68) | 0.694 |
| IL-6 (pg/mL) | 3.81(2.8-6.59) | 4.21(2.25-4.96) | 4.88(3.6-5.68) | 0.407 |
| IL-1β (pg/mL) | 1.1(0.26-2.3) | 1.08(0.22-1.66) | 1.17(0.83-1.94) | 0.618 |
| TNF-α(pg/mL) | 1.36(0-2.04) | 0.97(0.19-1.32) | 1.1(0.55-1.59) | 0.370 |
| MCP-1(pg/mL) | 43.58(23.61-112.64) | 103.15(56.29-179.88) | 139.08(99.63-163.99) | 0.002 |
| CDKN2A (ng/mL) | 2.9(2.26-5.57) | 5.63(2.86-11.76) | 7.65(4.78-15.16) | <0.001 |

p-value using Kruskal-Wallis test; MDA: malondialdehyde; oxLDL: oxidized LDL; IL-6: interleukin-6; IL-1β: interleukin- 1β; TNF-α: tumor necrosis factor- α; MCP-1: monocyte chemoattractant protein-1; CDKN2A: cyclin-dependent kinase inhibitor 2A;

Table S3:Oxidative stress, pro-inflammatory cytokines, and senescence markers in T2DM patients according to the glycemia

|  |  |  |
| --- | --- | --- |
| **Variables** | **HbA1c (%)** | **p-value** |
| **≤ 7.5%** | **> 7.5%** |
| MDA (µmol/L) | 7.9 (6.17-10.31) | 8.19 (6.84-9.83) | 0.908 |
| oxLDL (µg/mL) | 1.1 (0.64-1.67) | 1.03 (0.59-2.04) | 0.746 |
| IL-6 (pg/mL) | 3.98 (2.44-5.56) | 4.42 (2.81-5.94) | 0.596 |
| IL-1β (pg/mL) | 1.09 (0.27-1.59) | 1.19 (0.46-2.13) | 0.336 |
| TNF-α (pg/mL) | 1.0 (0.1-1.6) | 1.21 (0.35-1.58) | 0.775 |
| MCP-1 (pg/mL) | 97.57 (25.39-156.95) | 107.67 (61.66-168.12) | 0.159 |
| CDKN2A (ng/mL) | 3.99 (2.56-7.29) | 7.58 (3.64-15.02) | 0.020 |

p-value using Mann-Whitney U-test; MDA: malondialdehyde; oxLDL: oxidized LDL; IL-6: interleukin-6; IL-1β: interleukin- 1β; TNF-α: tumor necrosis factor- α; MCP-1: monocyte chemoattractant protein-1; CDKN2A: cyclin-dependent kinase inhibitor 2A;